A Pardanani

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. doi request reprint Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Ken H Lim
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:790-4. 2009
  2. doi request reprint How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 121:3085-94. 2013
  3. doi request reprint Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:312-6. 2013
  4. doi request reprint Systemic mastocytosis: disease overview, pathogenesis, and treatment
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 26:1117-28. 2012
  5. pmc IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
    A Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:693-9. 2012
  6. doi request reprint Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:401-11. 2012
  7. doi request reprint Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature
    Animesh Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Hematol 17:125-32. 2010
  8. doi request reprint Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:362-71. 2011
  9. ncbi request reprint Systemic mastocytosis: bone marrow pathology, classification, and current therapies
    A Pardanani
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Acta Haematol 114:41-51. 2005
  10. ncbi request reprint FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature
    A Pardanani
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:965-70. 2006

Detail Information

Publications114 found, 100 shown here

  1. doi request reprint Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Ken H Lim
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:790-4. 2009
    ....
  2. doi request reprint How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 121:3085-94. 2013
    ..A systematic approach to the diagnosis and treatment of indolent SM using a case-based approach of representative clinical scenarios is presented here...
  3. doi request reprint Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:312-6. 2013
    ..4; P = 0.002), and could be considered in future prognostic models for PMF...
  4. doi request reprint Systemic mastocytosis: disease overview, pathogenesis, and treatment
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Hematol Oncol Clin North Am 26:1117-28. 2012
    ..The treatment of adult systemic mastocytosis is highly individualized. This article presents an overview of systemic mastocytosis and describes its pathogenesis and treatment...
  5. pmc IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes
    A Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:693-9. 2012
    ..These observations reinforce the concept of distinct and prognostically relevant plasma cytokine signatures in hematological malignancies...
  6. doi request reprint Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:401-11. 2012
    ..Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extra-cutaneous organs...
  7. doi request reprint Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature
    Animesh Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Hematol 17:125-32. 2010
    ..The current review provides an update on prognosis and treatment of systemic mastocytosis, including investigational drug therapy...
  8. doi request reprint Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:362-71. 2011
    ..Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extracutaneous organs...
  9. ncbi request reprint Systemic mastocytosis: bone marrow pathology, classification, and current therapies
    A Pardanani
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Acta Haematol 114:41-51. 2005
    ..The BM pathology, consensus classification, and current therapies for MCD are further discussed in this article...
  10. ncbi request reprint FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature
    A Pardanani
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:965-70. 2006
    ..Lastly, we present a comprehensive review of the literature pertaining to FIP1L1-PDGFRA in order to address several key aspects of this mutation from a clinical standpoint...
  11. doi request reprint Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:3769-72. 2009
    ....
  12. doi request reprint Targeting myeloproliferative neoplasms with JAK inhibitors
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Hematol 18:105-10. 2011
    ..Here, we review the current experience with JAK inhibitors used for the treatment of myelofibrosis and polycythemia vera/essential thrombocythemia...
  13. ncbi request reprint Pathogenesis, clinical features, and treatment advances in mastocytosis
    A Pardanani
    Division of Hematology, Mayo Clinic, Mayo Building W10A, 200 First Street SW, Rochester, MN 55905, USA
    Best Pract Res Clin Haematol 19:595-615. 2006
    ..The pathogenesis of mastocytosis, its major clinical subtypes, and recent treatment advances are discussed in this chapter...
  14. ncbi request reprint Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2785-9. 2008
    ..Thus, host genetic variation may contribute to phenotypic diversity among myeloproliferative disorders, including in the presence of a shared disease allele...
  15. doi request reprint JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:457-9. 2008
    ..Our study also suggests that the natural history of a JAK2V617F-positive "occult" MPN might be different from that of a typical MPN...
  16. ncbi request reprint Dysregulated EVI1 expression in myeloid malignancies
    Animesh Pardanani
    Mayo Clinic, Division of Hematology, Rochester, MN 55905, USA
    Leuk Lymphoma 47:2443-4. 2006
  17. ncbi request reprint JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
    A Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 22:23-30. 2008
    ..for initial Phase I studies? Should JAK2V617F-negative MPD patients be included in the initial studies? What are the likely consequences of 'off-target' JAK3 and wild-type JAK2 inhibition? How should treatment responses be monitored?..
  18. doi request reprint A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 84:371-8. 2010
    ..The intent of this exercise is not to undermine the complexity of the disease or previous work by other investigators, but to come up with ideas for response criteria that are more practical and consider meaningful patient outcome...
  19. doi request reprint LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations
    A Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1713-8. 2010
    ....
  20. ncbi request reprint A role for tryptase in myeloid disorders?
    Animesh Pardanani
    Mayo Clinic, Division of Hematology, Rochester, MN 55905, USA
    Leuk Lymphoma 47:789-90. 2006
  21. doi request reprint CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
    A Pardanani
    Hematology Division, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:1441-5. 2009
    ..Overall, our data indicate that the JAK1/JAK2 selective inhibitor CYT387 has potential for efficacious treatment of MPN harboring mutated JAK2 and MPL alleles...
  22. doi request reprint Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 86:1013-6. 2011
    ..05). We conclude that while hypovitaminosis D is relatively common in MPN and MDS, its clinical relevance for prognosis is limited...
  23. doi request reprint IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1146-51. 2010
    ..This study shows a relatively high incidence of IDH mutations in blast-phase MPN, regardless of JAK2 mutational status, and the occurrence of similar mutations in chronic-phase PMF...
  24. pmc IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1302-9. 2010
    ..The current study clarifies disease- and stage-specific IDH mutation incidence and prognostic relevance in MPN and provides additional evidence for the biological effect of distinct JAK2 haplotypes...
  25. doi request reprint Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
    M M Patnaik
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 27:1504-10. 2013
    ..4-2.9) and leukemia-free survival (high risk, RR 4.9, 95% CI 1.9-12.8; intermediate risk, RR 2.6, 95% CI 1.1-5.9) performed better than other conventional risk models and was validated in an independent cohort of 268 CMML patients...
  26. doi request reprint Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 22:756-61. 2008
    ..We conclude that low V617F allele burden in PMF might indicate the presence of an overriding V617F-negative clone that confers a more aggressive disease phenotype...
  27. doi request reprint TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:905-11. 2009
    ..05). We conclude that TET2 mutations occur in both JAK2V617F-positive and -negative MPN, are more prevalent in older patients, display similar frequencies across MPN subcategories and disease stages, and hold limited prognostic relevance...
  28. doi request reprint Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates
    A Tefferi
    Divisions of Hematology and Hematopathology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 23:900-4. 2009
    ..98). We conclude that TET2 mutations are frequent in SM, segregate with KITD816V and influence phenotype without necessarily altering prognosis...
  29. doi request reprint Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients
    M M Patnaik
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:101-5. 2012
    ..0, 95% confidence interval 2.3-20.8). The presence of IDH2R140Q did not affect the overall (P=0.54) or leukemia-free (P=0.81) survival. The current study suggests a powerful adverse prognostic effect for mutant IDH1 in MDS...
  30. ncbi request reprint Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera
    A Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leukemia 21:1960-3. 2007
    ..However, similar BM morphologic changes can also be seen in some JAK2V617F-positive PV cases; therefore, distinct genotype-phenotype association cannot be established...
  31. doi request reprint JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leukemia 24:105-9. 2010
    ..Allelic distortion from acquired uniparental disomy contributes to the appearance of a more pronounced effect on disease susceptibility in VF-positive patients, when studying clonally affected tissue...
  32. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
    ..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...
  33. doi request reprint CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia
    A Pardanani
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1870-3. 2013
    ..Four CSF3RT618I-mutated cases co-expressed SETBP1 mutations. We conclude that CSF3RT618I is a highly sensitive and specific molecular marker for CNL and should be incorporated into current diagnostic criteria. ..
  34. doi request reprint The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients
    A Pardanani
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:110-4. 2010
    ..We conclude that JAK2 haplotype 46/1 confers susceptibility to developing ET independent of VF mutational status and does not seem to further affect the clinical phenotype or prognosis...
  35. pmc WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations
    M M Patnaik
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1283-9. 2010
    ....
  36. pmc IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 26:475-80. 2012
    ..Our observations suggest that IDH mutations in PMF are independent predictors of leukemic transformation and raise the possibility of leukemogenic collaboration with JAK2V617F...
  37. ncbi request reprint 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course
    C Vaklavas
    Department of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 31:691-4. 2007
    ..Two patients (25%) transformed into cutaneous T-cell lymphoma after 3-8 years of eosinophilic prodrome...
  38. pmc Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
    A Tefferi
    Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1874-81. 2013
    ..Leukemic transformation was associated with treatment exposure to pipobroman or P32/chlorambucil. We found no association between leukemic transformation and hydroxyurea or busulfan use...
  39. doi request reprint A phase-2 trial of low-dose pomalidomide in myelofibrosis
    K H Begna
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:301-4. 2011
    ..Grade 3 or 4 thrombocytopenia/neutropenia occurred in 2%/0% of patients. Low-dose pomalidomide is effective in the treatment of anemia associated with JAK2V617F-positive MF; response is predicted by early drug-induced basophilia...
  40. doi request reprint Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
    A Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:1834-9. 2011
    ..We conclude that the presence of mutant MPL has narrow and inconsistent phenotypic effect in PMF and does not influence overall or leukemia-free survival...
  41. ncbi request reprint Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine
    A Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 28:127-31. 2004
    ..Treatment was well tolerated and duration of remission in responding patients ranges from 2 months to 4+ years since the completion of treatment with 2-CdA...
  42. ncbi request reprint Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients
    A Pardanani
    Divisions of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 28:777-83. 2004
    ..In conclusion, CD25, but not CD2, is a reliable marker for neoplastic mast cells, and CD25 expression indicates histologically occult bone marrow infiltration and residual disease after therapy...
  43. ncbi request reprint CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 102:3093-6. 2003
    ..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD...
  44. doi request reprint Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 84:518-24. 2010
    ..The current study was designed to provide additional data in this regard...
  45. pmc Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Leukemia 27:1322-7. 2013
    ..CYT387 is well tolerated and produces significant anemia, spleen and symptom responses in MF patients. Plasma cytokine and gene expression studies suggested a broad anticytokine drug effect...
  46. ncbi request reprint A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia
    R A Mesa
    Division of Hematology, Rochester, MN, USA
    Leukemia 21:1964-70. 2007
    ..8 nM) seen in pretreatment samples. The current study indicates both in vitro and in vivo tipifarnib activity in PMF and post-PV/ET MF...
  47. ncbi request reprint TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
    A Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 21:1658-68. 2007
    ..Therapeutic efficacy of TG101209 was demonstrated in a nude mouse model. Furthermore, TG101209 suppressed growth of hematopoietic colonies from primary progenitor cells harboring JAK2V617F or MPL515 mutations...
  48. ncbi request reprint Imatinib for systemic mast-cell disease
    A Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, USA
    Lancet 362:535-6. 2003
    ..The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase...
  49. ncbi request reprint Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 28:S47-52. 2004
    ..These observations make it necessary to re-examine current disease classification and treatment algorithms in eosinophilic disorders...
  50. ncbi request reprint Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
    Jaya Kittur
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2279-84. 2007
    ..A possible association with thrombotic complication has also been considered...
  51. doi request reprint JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations
    A Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 25:218-25. 2011
    ....
  52. doi request reprint The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea
    Shireen Sirhan
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:363-5. 2008
    ..02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV...
  53. ncbi request reprint Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 104:1931-9. 2004
    ..Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia...
  54. doi request reprint Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Am J Hematol 85:238-42. 2010
    ..We conclude that neither the SCLL phenotype nor blood eosinophilia is a consistent feature of FGFR1-associated 8p11.2 translocations; conversely, FISH might not always reveal FGFR1 involvement in typical SCLL...
  55. doi request reprint AKT is a therapeutic target in myeloproliferative neoplasms
    I Khan
    Division of Hematology, Northwestern University, Chicago, IL, USA
    Leukemia 27:1882-90. 2013
    ..Together, these findings establish AKT as a rational therapeutic target in the MPNs. ..
  56. ncbi request reprint Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates
    Naseema Gangat
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:197-200. 2008
    ..02), but not JAK2V617F allele burden, thrombosis, hemorrhage, leukemic/fibrotic transformation, or survival. We conclude that cytogenetic anomalies occur infrequently at PV diagnosis and do not confer an adverse outcome...
  57. ncbi request reprint Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:3391-7. 2003
    ..Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy...
  58. ncbi request reprint Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:739-42. 2003
    ..In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia...
  59. doi request reprint KIT and mastocytosis
    Ken Hong Lim
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Acta Haematol 119:194-8. 2008
    ..In general, conventional therapy for SM is suboptimal, and efforts are under way to develop and employ small molecule drugs that target mutant KIT...
  60. ncbi request reprint Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time
    Terra L Lasho
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 135:683-7. 2006
    ..We conclude that MPLW515L/K and JAK2V617F are both early events in MMM and allele burden, rather than the mere presence of these mutations, might be relevant to phenotypic variation in myeloproliferative disorders...
  61. ncbi request reprint Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Stem Cells 25:2358-62. 2007
    ..These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell...
  62. pmc Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium
    A Tefferi
    Division of Hematology, Department of Medicine, Rochester, MN, USA
    Blood Cancer J 1:e7. 2011
    ....
  63. doi request reprint Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:14-7. 2010
    ..We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes...
  64. doi request reprint Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1356-63. 2011
    ..This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance...
  65. pmc Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
    Michelle Ann Elliott
    Division of Hematology Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 95:1788-91. 2010
    ..007) and venous (P=0.02) thromboses were analyzed separately. The current study demonstrates a higher prevalence of venous, as opposed to arterial, events in PMF, post-diagnosis, and clarifies their nature as being mostly provoked...
  66. doi request reprint Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:789-96. 2011
    ..Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor...
  67. doi request reprint DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
    Naseema Gangat
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:392-7. 2011
    ..The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status...
  68. pmc Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:158-64. 2010
    ..In the current review, we provide a simplified algorithm for distinguishing the various causes of clonal and idiopathic eosinophilia and discuss current therapy, including new drugs (imatinib mesylate, alemtuzumab, and mepolizumab)...
  69. pmc Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients
    Carrie A Thompson
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:171-3. 2010
    ..Optimal management of AL patients with FX deficiency undergoing invasive procedures remains to be determined...
  70. doi request reprint Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not
    Ayalew Tefferi
    Division of Hematology Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:265-7. 2009
    ..003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value...
  71. ncbi request reprint Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2083-8. 2007
    ..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
  72. ncbi request reprint Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests
    Ayalew Tefferi
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:599-604. 2007
    ....
  73. ncbi request reprint Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
    Naseema Gangat
    Division of Hematology, Department of Medicine, Laboratory Medicine, and Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 138:354-8. 2007
    ..The current study highlighted the prognostic relevance of leucocytosis on various aspects of the disease in PV...
  74. ncbi request reprint MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 91:ECR57. 2006
    ....
  75. ncbi request reprint Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease
    Animesh Pardanani
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 13:384-91. 2007
    ..In addition, a number of new drugs are currently being tested for their safety and efficacy in all 3 disorders...
  76. ncbi request reprint Eosinophilia: secondary, clonal and idiopathic
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:468-92. 2006
    ..The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment...
  77. doi request reprint 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:386-90. 2008
    ....
  78. ncbi request reprint Atypical myeloproliferative disorders: diagnosis and management
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:553-63. 2006
    ....
  79. ncbi request reprint Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease
    Jin Young Baek
    Division of Hematopathology and Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 26:83-90. 2002
    ..The results confirm the diagnostic value of Kit immunohistochemistry in MCD and suggest a biologically relevant heterogeneity in TGFbeta1R expression among patients with SMCD-HD...
  80. ncbi request reprint Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  81. ncbi request reprint Clinical, genetic, and therapeutic insights into systemic mast cell disease
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Hematol 11:58-64. 2004
    ..The purpose of this review is to summarize current concepts and recent advances in the pathogenesis and treatment of adult mast cell disease...
  82. ncbi request reprint Mutation screening for JAK2V617F: when to order the test and how to interpret the results
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:739-44. 2006
    ..Therefore, mutation screening for JAK2V617F can be considered as a myeloid-specific clonality assay and it is diagnostically most useful in the evaluation of "polycythemia"...
  83. ncbi request reprint Systemic mastocytosis: current concepts and treatment advances
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Curr Hematol Rep 3:197-202. 2004
    ..Cladribine has been shown to be effective in patients who develop resistance to interferon treatment...
  84. ncbi request reprint Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Hematol 79:441-7. 2004
    ..The bone marrow histologic phenotype of these imatinib-sensitive eosinophilic disorders includes systemic mastocytosis, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, and atypical chronic myeloproliferative disorder...
  85. doi request reprint Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
    Kebede Hussein
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 82:255-9. 2009
    ..The presence of 0, 1, 2, and > or =3 adverse factors defines low, intermediate-1, intermediate-2, and high risk disease, respectively. We examined the additional prognostic relevance of karyotype...
  86. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  87. doi request reprint Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN, USA
    Leuk Res 33:662-4. 2009
    ..This preliminary report suggests a potential value for array CGH in terms of both clinical diagnostics and genomic research in MPNs...
  88. doi request reprint JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective
    A Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Blood Rev 25:229-37. 2011
    ..It is our impression that many more JAK inhibitors need to be evaluated in order to identify the best-in-class in terms of efficacy, toxicity and suitability for future combination treatment programs...
  89. ncbi request reprint Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:883-5. 2003
    ..The clinical implications of this finding are discussed...
  90. ncbi request reprint Treatment of hypereosinophilic syndrome with imatinib mesilate
    Gerald J Gleich
    Department of Immunology, Allergic Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, MN, USA
    Lancet 359:1577-8. 2002
    ..All patients who responded stopped other treatments and reduced imatinib mesilate to 200 mg per week. This drug effectively controls eosinophilia in patients with hypereosinophilic syndrome and normal interleukin-5 concentrations...
  91. ncbi request reprint Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1169-75. 2002
    ..To study clinicopathologic correlations and identify prognostically important variables in patients with systemic mast cell disease (SMCD) who have no associated hematologic disorders...
  92. ncbi request reprint Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder
    Animesh Pardanani
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 120:691-4. 2003
    ..04). Furthermore, no correlation was found between mast cell CD2 expression and other clinicopathological features in these patients...
  93. ncbi request reprint Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:827-30. 2003
    ..008). The prognostic value of circulating PBPCs may help select treatment for patients with AL...
  94. ncbi request reprint Bone marrow angiogenesis in systemic mast cell disease
    Jin Young Baek
    Divisions of Hematopathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Hematother Stem Cell Res 11:139-46. 2002
    ..We conclude that bone marrow angiogenesis characterizes a percentage of patients with SMCD and that the pathogenesis may not necessarily be linked to the mast cells themselves...
  95. doi request reprint Risk factors for leukemic transformation in patients with primary myelofibrosis
    Jocelin Huang
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 112:2726-32. 2008
    ..However, to the authors' knowledge, information regarding risk factors for leukemic transformation in primary myelofibrosis is limited...
  96. doi request reprint Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis
    Naseema Gangat
    Division of Hematology, Department of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota55905, USA
    Am J Hematol 83:451-3. 2008
    ..30%; P = 0.003). Multivariable analysis revealed that these associations were independent of other risk factors for thrombosis. High JAK2V617F allele burden clustered with pruritus (P = 0.002) but did not affect thrombosis rates...
  97. pmc TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells
    Vijay Ramakrishnan
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:675-86. 2010
    ..Our results provide the rationale for clinical evaluation of TG101209 alone or in combination with PI3K/Akt inhibitors in MM...
  98. ncbi request reprint A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2534-41. 2003
    ..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
  99. doi request reprint Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations
    Meredith A Lakey
    Division of Hematopathology Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Am J Clin Pathol 133:942-8. 2010
    ..Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), together with the bone marrow findings of erythroid hyperplasia and subtle megakaryocytic atypia, should prompt an evaluation for an exon 12 mutation...
  100. ncbi request reprint 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:301-6. 2003
    ..To evaluate the efficacy of 2-chlorodeoxyadenosine (2-CDA), a purine nucleoside analogue, in treating disseminated Langerhans cell histiocytosis (LCH)...
  101. pmc Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years
    Rakhee Vaidya
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1114-9. 2009
    ..002), not in those with low-risk disease (P=.42). These observations are encouraging and suggest a salutary effect from modern therapeutic approaches in PMF...